LLY

1,044.57

-0.66%↓

JNJ

243.69

-1%↓

ABBV

232.05

+1.51%↑

NVS

162.63

+0.37%↑

MRK

121.53

+0.86%↑

LLY

1,044.57

-0.66%↓

JNJ

243.69

-1%↓

ABBV

232.05

+1.51%↑

NVS

162.63

+0.37%↑

MRK

121.53

+0.86%↑

LLY

1,044.57

-0.66%↓

JNJ

243.69

-1%↓

ABBV

232.05

+1.51%↑

NVS

162.63

+0.37%↑

MRK

121.53

+0.86%↑

LLY

1,044.57

-0.66%↓

JNJ

243.69

-1%↓

ABBV

232.05

+1.51%↑

NVS

162.63

+0.37%↑

MRK

121.53

+0.86%↑

LLY

1,044.57

-0.66%↓

JNJ

243.69

-1%↓

ABBV

232.05

+1.51%↑

NVS

162.63

+0.37%↑

MRK

121.53

+0.86%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

5.74 -1.54

Rezumat

Modificarea prețului

24h

Curent

Minim

5.73

Maxim

6

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+21.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

16 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

50M

288M

Deschiderea anterioară

7.28

Închiderea anterioară

5.74

Sentimentul știrilor

By Acuity

50%

50%

160 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 feb. 2026, 23:57 UTC

Acțiuni populare

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb. 2026, 23:35 UTC

Câștiguri
Principalele dinamici ale pieței

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb. 2026, 23:28 UTC

Câștiguri

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb. 2026, 21:47 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb. 2026, 23:33 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb. 2026, 22:55 UTC

Câștiguri
Acțiuni populare

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb. 2026, 22:23 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb. 2026, 21:57 UTC

Câștiguri

XP 4Q Rev BRL4.95B >XP

12 feb. 2026, 21:52 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 feb. 2026, 21:47 UTC

Câștiguri

Morningstar 4Q Rev $641M >MORN

12 feb. 2026, 21:39 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:38 UTC

Câștiguri

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

21.56% sus

Prognoză pe 12 luni

Medie 7.5 USD  21.56%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

160 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat